methylprednisolone + rosuvastatin

This is a combination of two pharmaceutical drugs, methylprednisolone and rosuvastatin. Methylprednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, used to treat a wide range of inflammatory and autoimmune conditions. It acts primarily by binding to the glucocorticoid receptor, modulating gene expression to suppress pro-inflammatory cytokines and immune responses[3][9]. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis in the liver. It reduces LDL cholesterol, increases HDL cholesterol, lowers triglycerides, and has pleiotropic effects such as improving endothelial function and reducing vascular inflammation[2][6][8]. The combination may be considered for patients who require both anti-inflammatory therapy (e.g., for autoimmune or inflammatory diseases) and lipid-lowering therapy (e.g., for cardiovascular risk reduction). There are limited data on fixed-dose combinations; co-administration should be monitored due to potential drug interactions.